Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Triple negative
•
Breast Cancer, Metastatic
What initial treatment would you offer a patient with metastatic triple negative breast cancer with somatic BRCA1/2 mutation, CPS <10?
Is there a role of olaparib in light of TBCRC 048 data showing response in somatic mutations?
Related Questions
How are you considering use of inavolisib/palbociclib/fulvestrant over ET doublets for patients with high risk disease features such as visceral metastases, visceral crisis, high tumor burden?
In which breast cancer presentation would you consider earlier treatment with T-DXd, given the similar absolute PFS benefits seen with T-DXd in the DESTINY-Breast06 trial and DESTINY-Breast04 trials?
What are your top takeaways in Breast Cancer from ASCO 2025?
What are your top takeaways in Radiation Oncology from SABCS 2024?
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
What are your top takeaways in Breast Cancer from ESMO 2024?
Do you continue ovarian suppression for metastatic hormone-positive breast cancer patients who are premenopausal, regardless of line of therapy?
What are your top takeaways in Breast Cancer from ASTRO 2024?
In patients with advanced HR+, HER2- breast cancer who have progressed on first-line CDK 4/6i and ET and found to have ESR1 mutation, are you offering combination of abemaciclib and elacestrant in the 2nd line or SERD monotherapy?
What supportive care measures do you prioritize to manage or prevent toxicity in patients receiving Dato-DXd?